NASDAQ: PHARPharming Group Nv Stock
$10.25-0.06 (-0.58%)
Updated Jul 18, 2025
PHAR Price
$10.25
Fair Value Price
N/A
Market Cap
$697.59M
52 Week Low
$6.65
52 Week High
$12.61
P/E
-42.9x
P/B
2.87x
P/S
1.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$364.44M
Earnings
-$15.34M
Gross Margin
89%
Operating Margin
-1.09%
Profit Margin
-4.4%
Debt to Equity
0.88
Operating Cash Flow
$7M
Beta
0.52
Next Earnings
Jul 31, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PHAR Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PHAR's potential to beat the market
- PHAR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PHAR
RankedUnranked of 476
RankedUnranked of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.40 | A | |
| $8.63 | A | |
| $67.86 | A |
Be the first to know about important PHAR news, forecast changes, insider trades & much more!
PHAR News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PHAR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHAR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHAR is good value based on its book value relative to its share price (2.87x), compared to the US Biotechnology industry average (4.56x)
P/B vs Industry Valuation
PHAR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PHAR due diligence checks available for Premium users.
Valuation
PHAR fair value
Fair Value of PHAR stock based on Discounted Cash Flow (DCF)
Price
$10.25
Fair Value
$1.02
Overvalued by
900.21%
PHAR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PHAR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-42.9x
Industry
-179.53x
Market
31.42x
PHAR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.87x
Industry
4.56x
PHAR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHAR's financial health
Profit margin
Revenue
$86.0M
Net Income
-$16.0M
Profit Margin
-18.6%
PHAR's Earnings (EBIT) of -$3.96M... subscribe to Premium to read more.
Interest Coverage Financials
PHAR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$438.2M
Liabilities
$204.2M
Debt to equity
0.88
PHAR's short-term assets ($243.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHAR's short-term assets ($243.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHAR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$252.2k
Investing
$10.5M
Financing
-$7.3M
PHAR's operating cash flow ($6.91M)... subscribe to Premium to read more.
Debt Coverage Financials
PHAR vs Biotech Stocks
Pharming Group Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.